Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies

Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clinical use. However, Top2-based chemotherapy has been associated with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients. This association is suggestive of a link between carcinogenesis and Top2-mediated DNA damage. We show here that VP-16-induced carcinogenesis involves mainly the β rather than the α isozyme of Top2. In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is found to be significantly higher in TOP2β+ than in skin-specific top2β-knockout mice. Furthermore, VP-16-induced DNA sequence rearrangements and double-strand breaks (DSBs) are found to be Top2β-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the importance of proteasomal degradation of the Top2β-DNA cleavage complexes in VP-16-induced DNA sequence rearrangements. VP-16 cytotoxicity in transformed cells expressing both Top2 isozymes is, however, found to be primarily Top2α-dependent. These results point to the importance of developing Top2α-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.

[1]  L. Liu,et al.  Nucleolytic Cleavage of the Mixed Lineage Leukemia Breakpoint Cluster Region during Apoptosis* , 2001, The Journal of Biological Chemistry.

[2]  M. Amylon,et al.  HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. , 1993, Blood.

[3]  P. Kaufman,et al.  Reduction of collagen type I in the ciliary muscle of inflamed monkey eyes. , 1999, Investigative ophthalmology & visual science.

[4]  Chao-Po Lin,et al.  Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia. , 2006, Cancer research.

[5]  J. Rowley,et al.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. McMahon,et al.  Sonic hedgehog regulates growth and morphogenesis of the tooth. , 2000, Development.

[7]  D. Head,et al.  Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). , 1995, Leukemia.

[8]  N. Osheroff,et al.  Etoposide, topoisomerase II and cancer. , 2005, Current medicinal chemistry. Anti-cancer agents.

[9]  James C. Wang,et al.  Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIβ , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Zeleznik-Le,et al.  Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. , 1996, Blood.

[11]  K. Fitzgerald,et al.  Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. , 2000, The Journal of biological chemistry.

[12]  C. Felix.  Leukemias related to treatment with DNA topoisomerase II inhibitors. , 2001, Medical and pediatric oncology.

[13]  Chao-Po Lin,et al.  A Protease Pathway for the Repair of Topoisomerase II-DNA Covalent Complexes* , 2006, Journal of Biological Chemistry.

[14]  M. Stanulla,et al.  DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis , 1997, Molecular and cellular biology.

[15]  Chun-Yuan Ting,et al.  26 S Proteasome-mediated Degradation of Topoisomerase II Cleavable Complexes* , 2001, The Journal of Biological Chemistry.

[16]  L. Liu,et al.  Tumor cell death induced by topoisomerase-targeting drugs. , 2001, Annual review of pharmacology and toxicology.

[17]  F. Zunino,et al.  Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180). , 1996, Molecular pharmacology.

[18]  D. J. Clarke,et al.  A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells , 1994, Nature.

[19]  A. Tokunaga,et al.  Involvement of DNA Topoisomerase IIβ in Neuronal Differentiation* , 2001, The Journal of Biological Chemistry.

[20]  E. Fuchs,et al.  Interleukin 6: insights to its function in skin by overexpression in transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Uemura,et al.  DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe , 1987, Cell.

[22]  W. T. Beck,et al.  DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. , 1995, Oncology research.

[23]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[24]  M. Diaz,et al.  Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity , 2005, Leukemia.

[25]  J. Rowley,et al.  The critical role of chromosome translocations in human leukemias. , 1998, Annual review of genetics.

[26]  C. Croce,et al.  Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia. , 1993, Cancer research.

[27]  Masahiko Watanabe,et al.  Differential expressions of the topoisomerase IIα and IIβ mRNAs in developing rat brain , 1994, Neuroscience Research.

[28]  C. Felix.  Secondary leukemias induced by topoisomerase-targeted drugs. , 1998, Biochimica et biophysica acta.

[29]  J. Sng,et al.  Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. , 1993, Biochimica et biophysica acta.

[30]  M. Diaz,et al.  Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. , 2001, Cancer research.

[31]  M. Diaz,et al.  Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. , 2003, Cancer research.

[32]  R. Sternglanz,et al.  DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Mclaughlin,et al.  Antigen retrieval in cryostat tissue sections and cultured cells by treatment with sodium dodecyl sulfate (SDS) , 1996, Histochemistry and Cell Biology.

[34]  C. Croce,et al.  Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. , 1994, Cancer research.

[35]  M. Tilby,et al.  Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. , 1998, Molecular pharmacology.

[36]  J. Rowley,et al.  An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. , 1998, Blood.

[37]  Chao-Po Lin,et al.  Role of Topoisomerase IIβ in the Expression of Developmentally RegulatedGenes , 2006, Molecular and Cellular Biology.

[38]  Jin-Ming Yang,et al.  Acidic pH induces topoisomerase II-mediated DNA damage , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Michael L. Cleary,et al.  Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias , 1992, Cell.

[40]  A. Tokunaga,et al.  Immunohistochemical analyses of DNA topoisomerase II isoforms in developing rat cerebellum , 2001, The Journal of comparative neurology.

[41]  B. Roe,et al.  DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis. , 2000, Human molecular genetics.

[42]  M. Stanulla,et al.  Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. , 1996, Blood.

[43]  M. Andersen,et al.  Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. , 2002, Blood.

[44]  J. Wang,et al.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Nowell,et al.  Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. , 1991, Cancer research.

[46]  F. Zunino,et al.  Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. , 1992, Biochimica et biophysica acta.

[47]  J. Rowley,et al.  Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16) , 2004, Genes, chromosomes & cancer.

[48]  D. Botstein,et al.  DNA topoisomerase II is required at the time of mitosis in yeast , 1985, Cell.

[49]  L. Liu,et al.  Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. , 1990, Cancer research.

[50]  Y. Pommier,et al.  Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. , 2001, Biochemistry.

[51]  G. Evans,et al.  A trithorax–like gene is interrupted by chromosome 11q23 translocations in acute leukaemias , 1992, Nature Genetics.